DMT

The Imperial College London's Centre for Psychedelic Research will run the first clinical trial of depression treatment with the psychedelic and illegal substance dimethyltryptamine (DMT). It will be held in in collaboration with Small Pharma, with a neuropharmaceutical company.

Small Pharma stated that the approval is a "truly ground-breaking moment" in the treatment of depression and the chief medical and scientific officer at the company, Carol Routledge, has added that she believes that "Psychedelic assisted therapy will revolutionise the treatment of depression because it gets right to the root cause of the illness".